Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 and SI-B003 in recurrent/metastatic head and neck squamous cell carcinoma
NCT06006169Phase 2Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Oct 2023
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab brengitecan in head and neck squamous cell carcinoma (HNSCC), sponsored by Biokin Pharmaceutical. Started Oct 2023; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06006169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06006169.